🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Haemophilia A

Hemlibra in Mild Hemophilia A NCT04567511Phase 41 site📍 Indianapolis Indiana Hemophilia &Thrombosis Center, Inc. · Tests: Emicizumab A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab NCT06145373Phase 43 sites📍 Los Angeles📍 Flowood📍 Taipei Sanofi · Tests: Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC),… Multimodal Telerehabilitation Versus Face-to-Face Care for Adults With Hemophilia and Chronic Pain NCT07682519NA1 site📍 Santiago University of Chile · Tests: other, Exercise Monitoring of Anti-TFPI in Hemophilia NCT07101926n/a2 sites📍 Bron📍 Paris Hospices Civils de Lyon · Tests: blood sampling A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B NCT06379789Phase 1, Phase 252 sites📍 Phoenix📍 Los Angeles📍 Los Angeles Regeneron Pharmaceuticals · Tests: REGV131, LNP1265 Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients. NCT07437404Phase 31 site📍 Beijing Sinocelltech Ltd. · Tests: SCT800 prophylaxis and treatment for bleeding events Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old NCT05709288Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: BBM-H901 Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders NCT06147414n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: Blood sample A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI NCT02207894n/a1 site📍 Frankfurt am Main Haemophilia Centre Rhine Main A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B NCT05611801Phase 363 sites📍 Salt Lake City📍 Mendoza📍 Parkville Pfizer · Tests: marstacimab Patient Reported Outcomes Burdens and Experiences - Phase 3 NCT03549858n/a1 site📍 Hamilton McMaster University · Tests: Quality of life measure (survey) An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A NCT05849740Phase 41 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Daratumumab and corticosteroid treatment ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders NCT04398628n/a76 sites📍 Phoenix📍 Little Rock📍 Los Angeles American Thrombosis and Hemostasis Network A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia A NCT07787091Phase 1, Phase 21 site📍 Singapore Arditus Pte Ltd · Tests: ARD001, Placebo Validity and Reliability of the Figure-of-Eight Walking and Weight-Bearing Lunge Tests in Hemophilia NCT07851922n/a1 site📍 Van Yuzuncu Yil University Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients NCT03695978n/a59 sites📍 Miami📍 New Orleans📍 St Louis Octapharma Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry NCT06992076n/a2 sites📍 Xiamen📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Marstacimab Safety and Efficacy Study of NGGT003 in Hemophilia A Patients NCT06238908EARLY Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: NGGT003 World Bleeding Disorders Registry NCT03327779n/a1 site📍 Montreal World Federation of Hemophilia To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A NCT06833983Phase 313 sites📍 Hefei📍 Beijing📍 Lanzhou Gritgen Therapeutics Co., Ltd. · Tests: GS1191-0445 injection The CACHE Study: Coronary Artery Care in HaEmophilia NCT06706206n/a1 site📍 Oxford Oxford University Hospitals NHS Trust · Tests: Observational trial German Pediatric Hemophilia Research Database NCT02912143n/a1 site📍 Frankfurt am Main Goethe University · Tests: documentation only A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea NCT06550882n/a4 sites📍 Seoul📍 Seoul📍 Seoul Takeda · Tests: OBIZUR A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B NCT07285460Phase 341 sites📍 Los Angeles📍 Los Angeles📍 Orange Sanofi · Tests: Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC) Embolization in Hereditary Coagulopathies NCT05629130NA1 site📍 São Paulo University of Sao Paulo General Hospital · Tests: embolization with spherical microparticles embosphere Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) NCT04278404n/a52 sites📍 Phoenix📍 Little Rock📍 Los Angeles Duke University · Tests: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the fol… Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study NCT05935358Phase 418 sites📍 Dallas📍 Zagreb📍 Helsinki Octapharma · Tests: Nuwiq Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis NCT05022459n/a10 sites📍 Little Rock📍 Palo Alto📍 San Diego Wayne State University · Tests: Emicizumab, FVIII A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency) NCT06349473Phase 110 sites📍 Glendale📍 Los Angeles📍 Chicago Equilibra Bioscience LLC · Tests: SR604, Placebo A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A NCT07416604Phase 359 sites📍 Orange📍 Aurora📍 Miami Hoffmann-La Roche · Tests: NXT007, Emicizumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy